An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.

Trial Profile

An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Tapentadol (Primary) ; Tapentadol (Primary)
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 03 Jul 2012 New source identified and integrated: European Clinical Trials Database record 2009-010427-12.
    • 16 Apr 2012 Actual patient number is 208 according to ClinicalTrials.gov.
    • 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top